AstraZeneca, Accent Launch Up To $1.1B+ Cancer Collaboration Targeting RNA-Modifying Proteins
AstraZeneca will partner with Accent Therapeutics to discover, develop, and commercialize cancer therapeutics based on Accent’s RNA-modifying protein (RMP) inhibition technology, the companies said today, through a collaboration that could…
Share